Abbott Laboratories · Health Care
$104.89
As of: 2026-10-18 01:54:27 (KST)
-45.2%
Expected return
25%
Success probability
-48.7%
Downside risk
For informational purposes only.
Not investment advice.
Abbott Laboratories in the Health Care industry carries C grade, driven by a Monte Carlo rating of 11. With an expected return of -45.2% and a 25% chance of positive returns, the stock at $104.89 presents
This assessment is based on 10,000 probabilistic scenarios, offering a robust view of the potential return distribution across varying market conditions.
The Reverse DCF analysis places this stock in the "Expensive" zone. The implied growth rate (g_implied) of 42.8%, compared with the actual growth rate of 4.8%, reveals the market's pricing assumptions. The P50 intrinsic value sits at $56, offering a reference point against the current price.
At $101, the Reverse-DCF implied probability of finishing above $101 stands at 0%.
This C rating (11) suggests caution. The expected return of -45.2% and 25% success probability are below our threshold for an attractive entry.
The Monte Carlo distribution reveals a volatility of 3.3% — relatively low, meaning the simulated outcomes cluster tightly around the median. The P50 sits at -45.9%, with a +5.1% gap between P10 (-48.7%) and P75 (-43.5%). a negative skew suggests downside scenarios are more pronounced than upside ones
In the worst 5% of scenarios, the 5th percentile value-at-risk is -48.7%. On the operating side, at 15.8%, operating margins are adequate but could compress under competitive pressure. With a volatility of 3.3%, volatility risk is low at the current price of $105.
Data: Finnhub
DCF estimates a company's intrinsic value by discounting its future cash flows to present value. Modelvix uses Monte Carlo simulation to analyze thousands of scenarios.
Learn more →WACC is the average rate a company pays to finance its assets, used as the discount rate in DCF analysis. Modelvix simulates how WACC changes affect valuation.
Learn more →Terminal value represents the perpetual value of a business beyond the forecast period, often comprising the majority of DCF value. Modelvix analyzes terminal value uncertainty across growth scenarios.
Learn more →Reverse DCF works backward from the current stock price to infer the growth rate the market expects, helping you assess whether a stock is fairly valued. Modelvix shows what growth assumptions the current price implies.
Learn more →